Issue 44, 2022

Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Abstract

Ruthenium complex is an important compound group for antitumor drug research and development. NAMI-A, KP1019, TLD1433 and other ruthenium complexes have entered clinical research. In recent years, the research on ruthenium antitumor drugs has not been limited to single chemotherapy drugs; other applications of ruthenium complexes have emerged such as in combination therapy. During the development of ruthenium complexes, drug delivery forms of ruthenium antitumor drugs have also evolved from single-molecule drugs to nanodrug delivery systems. The review summarizes the following aspects: (1) ruthenium complexes from monotherapy to combination therapy, including the development of single-molecule compounds, carrier nanomedicine, and self-assembly of carrier-free nanomedicine; (2) ruthenium complexes in the process of ADME in terms of absorption, distribution, metabolism and excretion; (3) the applications of ruthenium complexes in combination therapy, including photodynamic therapy (PDT), photothermal therapy (PTT), photoactivated chemotherapy (PACT), immunotherapy, and their combined application; (4) the future prospects of ruthenium-based antitumor drugs.

Graphical abstract: Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Article information

Article type
Review Article
Submitted
30 Maijs 2022
Accepted
11 Okt. 2022
First published
11 Okt. 2022
This article is Open Access
Creative Commons BY license

Nanoscale, 2022,14, 16339-16375

Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Y. Lu, D. Zhu, Q. Le, Y. Wang and W. Wang, Nanoscale, 2022, 14, 16339 DOI: 10.1039/D2NR02994D

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements